Komori
Pharmarise Holdings (2796) · RiskRestated

Risk of a Mismatch Between Consumption Tax Revisions and Drug Price Revisions

First written in FY2017. 3 of 4 entries say "Restated". Latest entry: FY2021.

4entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017 – FY20212017: 120172018: 120182019: 020192020: 120202021: 12021
Same theme, other companies
Earnings impact on the dispensing business from consumption tax rate changes and differences in drug price pass-throughA theme 7 companies write about · 7 as a headwind · 0 as a tailwind

4 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2021RestatedAnnual report

    「If the consumption tax rate is revised in the future and the revision is not taken into account in a drug price revision, it could affect the Group's results.」

    The risk of a mismatch between consumption tax rate revisions and drug price revisions continues.
  2. FY2020RestatedAnnual report

    「If the consumption tax rate is revised in the future and the revision is not taken into account in a drug price revision, it could affect the Group's results.」

    The risk of a mismatch between consumption tax rate revisions and drug price revisions continues to be disclosed.
  3. FY2018RestatedAnnual report

    「If the consumption tax rate is revised in the future and the revision is not taken into account in a drug price revision, it could affect the Group's results.」

    The risk of a mismatch between consumption tax rate revisions and drug price revisions continues to be disclosed.
  4. FY2017First statedAnnual report

    「If the consumption tax rate is revised in the future and the revision is not taken into account in a drug price revision, it could affect the Group's results.」

    The impact of a consumption tax rate revision was identified as a risk against the backdrop of the structural mismatch whereby dispensing revenue is tax-exempt while pharmaceutical purchases are taxable.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Pharmarise Holdings's next results are scheduled for 2026-09-17. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of a Mismatch Between Consumption Tax Revisions and Drug Price Revisions | Pharmarise Holdings Corporation (2796) | Komori